Arcturus Therapeutics Holdings Inc.
ARCT
$14.74
-$0.89-5.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 43.57% | -71.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 43.57% | -71.36% | |||
| Cost of Revenue | -18.64% | -12.05% | |||
| Gross Profit | 25.22% | -12.65% | |||
| SG&A Expenses | 16.10% | -32.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.03% | -19.51% | |||
| Operating Income | 11.70% | 7.59% | |||
| Income Before Tax | 11.79% | 7.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.79% | 7.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.79% | 7.27% | |||
| EBIT | 11.70% | 7.59% | |||
| EBITDA | 11.92% | 7.68% | |||
| EPS Basic | 11.80% | 8.28% | |||
| Normalized Basic EPS | 11.80% | 8.29% | |||
| EPS Diluted | 11.80% | 8.28% | |||
| Normalized Diluted EPS | 11.80% | 8.29% | |||
| Average Basic Shares Outstanding | 0.01% | 1.10% | |||
| Average Diluted Shares Outstanding | 0.01% | 1.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||